The latest review of the LSDP includes three cross program recommendations that do not even mention patients but emphasise the need for the program's underpinning principles to reflect 'pricing' policies.
Price limits, price cuts and price policies the focus of latest LSDP review
March 28, 2022 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
